Overexpression of TC2N is associated with poor prognosis in gastric cancer

Jianbo Xu (xjianb@mail.sysu.edu.cn)  
Sun Yat-sen University First Affiliated Hospital

Xinde Ou  
Sun Yat-sen University First Affiliated Hospital

Jin Li  
Sun Yat-sen University First Affiliated Hospital

Qinbo Cai  
Sun Yat-sen University First Affiliated Hospital

Kaiyu Sun  
Sun Yat-sen University First Affiliated Hospital

Jingning Ye  
Sun Yat-sen University First Affiliated Hospital

Jianjun Peng  
Sun Yat-sen University First Affiliated Hospital

Keywords: TC2N, Gastric cancer, Prognosis

Posted Date: July 6th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-39545/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Tac2-N (TC2N) is a tandem C2 domain-containing protein, acting as a novel oncogene or suppressor in different kinds of cancers. However, the status of TC2N expression and its significance in gastric cancer (GC) is still unclear. The present study is aimed to elucidate the clinicopathological significance and prognostic value of TC2N level in GC.

Methods

We used sequencing data from the Cancer Genome Atlas (TCGA) database to analyze TC2N expression in GC by UALCAN database and Gene Expression Profiling Interactive Analysis tools (GEPIA). TC2N expression level in 12 pairs of fresh GC tissues and adjacent nontumorous tissues was detected by quantitative real-time reverse-transcription polymerase chain reaction (RT-PCR) and Western blot (WB) assays. Immunohistochemical (IHC) staining was used to detect TC2N protein expression in Paraffin-embedded tissues in our center. In vitro proliferation, migration and invasion assays were used to evaluate the effect of TC2N on functional capability of gastric cancer cells. LinkedOmics was used to identify gene expressions associated with TC2N.

Results

The mRNA and protein expression of TC2N in gastric cancer were both significantly higher than normal gastric mucosa. It was also elevated in gastric cancer cells compared with normal gastric epithelium cell. In vitro assays suggested that TC2N facilitated proliferation, migration and invasion of gastric cancer cells. Bioinformatic analysis showed a widespread impact of TC2N on the transcriptome and a strong interaction with tumor associated genes. We also found that TC2N was an independent prognostic factor for long-term survival in GC patients and its high expression was significantly associated with poor overall survival and recurrence-free survival.

Conclusions

Our results show that high level of TC2N correlates with poor prognosis in patients with gastric cancer and promotes the development of gastric cancer. Thus, TC2N expression can serve as a prognostic biomarker for patients with gastric cancer.

Introduction

As the fifth most common cancer worldwide, gastric cancer (GC) is still incurable and induces 782,685 related death occurs in 2018 [1, 2]. A quantity of evidences show that GC remains an excessive health
burden in several Asian countries, especially in China, Korea and Japan [3, 4]. Despite the development of surgical techniques and the improvement of chemotherapy and radiotherapy regimens, gastric cancer, especially advanced gastric cancer, is still a dreadful disease with high mortality [5–8]. Due to the fact that convenient and effective methods in predicting the prognosis of patients with gastric cancer are still lacking [9, 10], novel biomarkers for improving early diagnosis, prognostic evaluation and tumor grading of GC are urgently needed.

Tac2-N (TC2N), located on human chromosome 14q32.12, encodes a putative C2 domain-containing protein that belongs to the carboxyl-terminal type (C-type) tandem C2 protein family. TC2N was first cloned in the mouse and contains two C-terminal C2 domains, C2A and C2B [11]. The C2 domain was originally identified as a protein structural domain of calcium-dependent protein kinase C [12–14]. Further studies indicated that the function of the C2 domain is not limited to calcium-dependent phospholipid binding since this motif has been implicated in cellular signal transduction and protein-protein interactions [15]. A number of proteins containing C2 domains are involved in the regulation of tumorigenesis. It is indicated that TC2N accelerates tumor progression in lung cancer by different mechanisms [16, 17]. Moreover, TC2N can also inhibit cell proliferation and tumor growth and correlates with a better prognosis in breast cancer [18]. However, the role TC2N playing in gastric cancer is still unclear.

The present study was undertaken to assess TC2N expression in GC specimens and explore its role in GC, and therefore to evaluate whether TC2N can serve as a prognostic biomarker for patients with GC.

Methods

Patients and specimens

Fresh gastric cancer and paired adjacent normal gastric mucosa tissues from resection specimens were collected from patients with primary gastric cancer who were treated by total or partial gastrectomy at the First Affiliated Hospital of Sun Yat-sen University (FAHSYSU) in 2017 (N = 12). All separated tissues were frozen immediately in liquid nitrogen and then stored in liquid nitrogen.

Paraffin-embedded tissues of gastric cancer and normal gastric mucosa were obtained from the Department of Pathology at the FAHSYSU. A total of 232 gastric cancer patients who underwent gastrectomy in our center were enrolled in this study. None of the patients received chemotherapy or other treatments before sampling. The pathological diagnoses and classifications were made according to the American Joint Committee on Cancer (AJCC) cancer staging manual, 7th ed [19]. Ethical approval for clinical research was obtained from the Institutional Review Board of FAHSYSU.

Cell culture

Gastric cancer cell lines, including AGS, MKN28 and HGC27, were obtained from the Type Culture Collection of Chinese Academy of Sciences (Shanghai, China). The normal gastric epithelial cell line GES1 was purchased from the Lab Animal Center of the Fourth Military Medical University (Shanxi, China). Cells
were maintained in DMEM (Invitrogen, USA) supplemented with 10% fetal bovine serum (GBICO, USA) in incubator with 5% CO2 and 95% room air at 37 °C.

**RNA isolation and reverse transcription-quantitative real-time PCR (RT-qPCR)**

RNA was isolated from the cell lines using the RNA isolation plus (TaKaRa, Japan). Single-stranded cDNA was generated from 1 µg total RNA in a 20µL reaction volume using oligo(dT) primers according to the protocol supplied with the Primer Script™ RT Reagent (TaKaRa, Japan). The relative expression levels were measured by qPCR using the ABI 7900HT instrument (Applied Biosystems, USA) in a total volume of 10 ul with the SYBR green detection system (Takara, Japan) and GAPDH was used as an endogenous control. Oligonucleotide sequences of the primer sets used were as follows: TC2N (forward: 5′-TGGCTGTACTGAGGATTATTTGC-3′, reverse: 5′-TGTGAAGGAGTTTCTTGTGTCC-3′); GAPDH (forward: 5′-ACAACCTTTGGATCGTGGAGG-3′, reverse: 5′-GCCATCACGCCACAGTTC-3′).

**Western blot**

For western blot analysis, total proteins from cell lines and fresh-frozen tissues were extracted using the Whole Cell Protein Extraction Kit (KeyGEN, China). BCA Protein Quantitation Assay (KeyGEN, China) was used to determine the protein concentration. An equal amount (30 µg) of protein sample was separated on 10% sodium dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and transferred to polyvinylidene fluoride membranes (PVDF) (Millipore, USA). The membranes were then blocked with 5% non-fat dry milk in Tris-buffered saline (TBS)/0.1% Tween 20 for 1 h at room temperature. Membranes were incubated with anti-TC2N (1:1000, PA5-26433, Invitrogen, USA), anti-β-actin (1:1000, 14395-1-AP, Proteintech, China,) primary antibodies overnight at 4 °C. The next day membranes were washed and incubated with horseradish peroxidase-conjugated secondary antibody. Proteins were visualized using Immobilon Western Chemiluminescent HRP Substrate (Millipore, USA).

**Immunohistochemical staining and evaluation**

The paraffin-embedded tissues were subjected to standard Immunohistochemical (IHC) staining, followed by streptavidin-biotin-peroxidase complex method as previous described [20]. In brief, slides were deparaffinized and then heated for antigen retrieval in EDTA buffer (pH 8.9) at 105 °C for 5 min and natural cooled for 30 min. Endogenous peroxidase activity was blocked in 3% hydrogen peroxide for 10 min. After blocked in 10% normal goat serum (KeyGen, China) for 30 min, sections were incubated with rabbit polyclonal anti-TC2N antibody (1:100, PA5-26433, Invitrogen, USA) at 4° overnight. EnVision Plus System-HRP (DAKO, Denmark) was used according to manufacturer’s instruction and targeted protein was visualized using diaminobenzidine (DAB) as the substrate. And the nucleus was displayed by Mayer’s hematoxylin counterstaining [21].

IHC results evaluation was performed by two double-blinded independent observers who were unaware of the clinical and pathological characteristics associated with the specimens, and scoring was determined using a semiquantitative method as previously described [22]. Samples in which more than 10% of the tumor cells were stained were considered positive. The staining intensity was defined as follows: 0
(negative), 1 (weak), 2 (moderate), and 3 (strong). Negative and weak staining was considered to indicate low TC2N expression, and moderate and strong staining was considered to indicate high TC2N expression.

**RNA interference and Plasmid construction**

Two different sequences of TC2N siRNA, including negative control siRNA, were designed and chemically synthesized by Ribobio (China). These two siRNA candidates were listed as follows: si-001 (targeting GGATAAGTGAAGACAGTAA) and si-002 (targeting GCACGGACCTAGCTATGAT). The expression vector encoding full-length open reading frame of human TC2N were constructed by synthesis and inserted into p3xFLAG-CMV-14. SiRNAs or plasmid were transfected to cells with the Lipofectamine 3000 reagent (Invitrogen, USA) following the manufacturer protocol.

**Cell Counting Kit-8 assay**

The Cell Counting Kit-8 (CCK8, Dojindo, Japan) was used according to the manufacturer’s instructions. Briefly, 1,000 cells/wells were seeded in a 96-well plate and 10 µl of CCK8 reagent were mixed with 90 µl of fresh medium to replace the original medium. Wells were further incubated for 3 h before being tested.

**Cell migration and invasion assays**

GC Cell migration and invasion were evaluated by conducting the Transwell assay, according to a previously described method [22]. Transwell inserts (pore size, 8 µm; BD Biosciences, USA) were specially precoated with Matrigel (BD Biosciences, USA) for use in the invasion assays. Infected AGS and MKN28 cells were harvested and 1 × 10^5 cells were suspended in 200 µL of serum-free medium and placed in a Transwell insert. The lower chamber was filled with 400 µL of medium containing 20% FBS. After the cells were incubated for 24 h at 37 °C, cells on the underside of the membrane were fixed with 4% paraformaldehyde for 15 min and subsequently stained with 0.1% crystal violet in 20% ethanol. Cell counts were performed for five randomly selected fields at × 100 magnification using phase contrast microscopy (Olympus, Germany). Transwell assays were replicated three times.

**Database analysis**

The mRNA expressions and tumor subgroup gene expressions of TC2N in GC tissues and normal gastric tissues were analyzed using the sequencing data from the Cancer Genome Atlas (TCGA) database [23] by UALCAN database [24] and Gene Expression Profiling Interactive Analysis tools (GEPIA) [25]. The LinkedOmics database [26] is a Web-based platform for analyzing 32 TCGA cancer-associated multidimensional datasets. The LinkFinder module of LinkedOmics was used to study genes differentially expressed in correlation with TC2N in the TCGA. Results were analyzed statistically using Spearman or Pearson’s correlation coefficient. Protein-protein interaction (PPI) networks were predicted using the Gene MANIA [27] and STRING program [28].

**Statistical analysis**

Statistical analysis and graphic plotting were performed using SPSS Statistics version 20.0 (IBM, USA) and GraphPad Prism version 6.0 (GraphPad Software, USA). Difference of TC2N mRNA expressions between groups was analyzed using Student’s t-test. The significance of associations between TC2N
expression and clinicopathological features was analyzed using the Chi-square test. Survival curves were plotted using Kaplan-Meier method and the difference between groups were compared using log-rank test. Hazards ratio for clinicopathological characteristics in univariate and multivariate analysis were both estimated with Cox proportional hazards regression. Two tailed test was used for all the statistical analysis and \( P \)-value < 0.05 was considered statistically significant.

**Results**

**The expression of TC2N is elevated in gastric cancer**

Firstly, we analyzed *TC2N* transcription levels in multiple GC studies from TCGA. Data in the UALCAN database revealed that the mRNA expression of *TC2N* was significantly higher in GC tissues than in normal tissues \( (P < 0.001) \) (Fig. 1A). Further sub-group analysis of multiple clinic pathological features of GC samples in the TCGA consistently showed that the transcription levels of *TC2N* were significantly higher in GC tissue than normal tissue in subgroup analyses based on gender, age, ethnicity, disease stages, tumor grade, *TP53* mutation and H.pylori infection (Fig. 1B-H). The mRNA level of *TC2N* in GC tissues and normal gastric tissues from the GEPIA database also showed an increase in gastric cancers compared with normal gastric tissues (Fig. 2A). Next, RT-qPCR was conducted on RNA samples derived from several gastric cancer cell lines and normal gastric epithelium cell line GES1. When compared with GES1, it was found that TC2N mRNA expressions were higher in AGS, MKN28 and HGC27 (Fig. 2B) and the tendency of protein level tested by western blot was in accordance with the RNA level (Fig. 2C). To further confirm the *TC2N* expression in gastric cancer samples, *TC2N* was detected by RT-qPCR and WB in 12 pairs of gastric cancer tissues and adjacent normal gastric mucosa. We found that both the mRNA and protein levels of *TC2N* were significantly elevated in gastric cancer tissues in comparison with adjacent normal gastric tissues (Fig. 2D, E). Thus, TC2N expression may serve as a potential diagnostic indicator in GC.

**Relationships between the expression of TC2N and clinicopathological features in gastric cancer**

To explore the associations between TC2N expression and GC clinicopathologic characteristics, firstly, we performed IHC to detect TC2N expression in the GC tissue array, which contained 55 cases of GC tissue and paired adjacent normal tissue from GC patients. As shown in Fig. 3, TC2N protein was distributed both in the nucleus and cytoplasm (Fig. 3A, B). Meanwhile, we found that the protein expression of TC2N was significantly higher in primary GC compared with adjacent normal tissues (Fig. 3C). Next, the expression of TC2N protein in 232 primary gastric cancer tissue samples was also detected by IHC, 55 of which was collected from the same cases with tissue array mentioned above. The patients included 159 males and 73 females, ranging in age from 27 to 83 years (mean 58.6 years). Patients were followed up for 1 to 84 months, with a median follow-up time of 51.2 months. As shown in Fig. 3D, there were 71 cases (30.6%) with IHC score 1, 78 cases (33.6%) with IHC score 2, 44 cases (19.0%) with IHC score 3, and 39 cases (16.8%) with negative staining (IHC score 0). Negative and weak staining were defined as low TC2N
expression (47.4%, 110/117), whereas moderate and strong staining were defined as high TC2N expression (52.6%, 122/117). The association between TC2N expression and clinicopathological features of this cohort was further evaluated. As shown in Table 1, High TC2N expression was associated with poorly differentiated histological classification ($P < 0.001$), large tumor size ($P < 0.05$), advanced distant metastasis ($P < 0.05$) and tumor-node-metastasis (TNM) stage ($P < 0.05$).
Table 1
Relationships between TC2N expression and clinical pathological parameters in gastric cancer

| Parameters                        | Cases number | TC2N expression | P value |
|----------------------------------|--------------|-----------------|---------|
|                                  |              | Low             | High    |         |
| Gender                           |              |                 |         | 0.862   |
| Male                             | 159 (68.5%)  | 76 (69.1%)      | 83 (68.0%) |         |
| Female                           | 73 (31.5%)   | 34 (30.9%)      | 39 (32.0%) |         |
| Age                              |              |                 |         | 0.926   |
| < 50                             | 47 (20.3%)   | 22 (20.0%)      | 25 (20.5%) |         |
| ≥ 50                             | 185 (79.7%)  | 88 (80.0%)      | 97 (79.5%) |         |
| Histological classification      |              |                 |         | < 0.001 |
| Well and moderately differentiated| 79 (34.1%)   | 54 (49.1%)      | 25 (20.5%) |         |
| Poorly differentiated            | 153 (65.9%)  | 56 (50.9%)      | 97 (79.5%) |         |
| Tumor size                       |              |                 |         | 0.014   |
| ≤ 4 cm                           | 109 (47.0%)  | 61 (55.5%)      | 48 (39.3%) |         |
| > 4 cm                           | 123 (53.0%)  | 49 (44.5%)      | 74 (60.7%) |         |
| Tumor location                   |              |                 |         | 0.944   |
| Upper stomach                    | 55 (23.7%)   | 27 (24.5%)      | 28 (22.9%) |         |
| Middle stomach                   | 34 (14.7%)   | 17 (15.5%)      | 17 (13.9%) |         |
| Lower stomach                    | 89 (38.4%)   | 40 (36.4%)      | 49 (40.2%) |         |
| More than two parts              | 54 (23.3%)   | 26 (23.6%)      | 28 (23.0%) |         |
| Depth of invasion                |              |                 |         | 0.516   |
| T1                               | 19 (8.2%)    | 8 (7.2%)        | 11 (9.0%) |         |
| T2                               | 30 (12.9%)   | 15 (13.6%)      | 15 (12.2%) |         |
| T3                               | 137 (59.1%)  | 61 (55.5%)      | 76 (62.3%) |         |
| T4                               | 46 (19.8%)   | 26 (23.6%)      | 20 (16.4%) |         |
| Lymph node metastasis            |              |                 |         | 0.184   |
| N0                               | 78 (33.6%)   | 42 (38.1%)      | 36 (29.5%) |         |
| N1                               | 80 (34.5%)   | 45 (40.9%)      | 35 (28.7%) |         |
| Parameters                  | Cases number | TC2N expression | P value |
|-----------------------------|--------------|-----------------|---------|
|                             |              | Low | High           |         |
| N2                          | 41 (17.7%)   | 15 (13.6%) | 26 (21.3%)    |         |
| N3                          | 33 (14.2%)   | 8 (7.3%)   | 25 (20.5%)    |         |
| Distant metastasis          |              |     | 0.032          |         |
| M0                          | 182 (78.4%)  | 93 (84.5%) | 89 (73.0%)    |         |
| M1                          | 50 (21.6%)   | 17 (15.5%) | 33 (27.0%)    |         |
| TNM stage                   |              | 0.020 |               |         |
| IA                          | 14 (6.0%)    | 8 (7.3%)   | 6 (4.9%)      |         |
| IB                          | 21 (9.1%)    | 14 (12.7%) | 7 (5.7%)      |         |
| II                          | 52 (22.4%)   | 29 (26.4%) | 23 (18.9%)    |         |
| IIIA                        | 47 (20.3%)   | 25 (22.7%) | 22 (18.0%)    |         |
| IIIB                        | 21 (9.1%)    | 5 (4.5%)   | 16 (13.1%)    |         |
| IV                          | 77 (33.2%)   | 29 (26.4%) | 48 (39.3%)    |         |

a: The pathological diagnoses and classifications were made according to American Joint Committee on Cancer (AJCC) cancer staging manual, 7th ed

**High TC2N expression indicated worse prognosis in patients with gastric cancer**

For all subjects in the present study, the follow-up period ranged from 1 to 84 months, with a median follow-up time of 51.2 months. And 123 (53.0%) patients were confirmed dead at the follow-up end point. The median overall survival time was 64.4 ± 11.6 months and the 5-year overall survival (OS) rate was 50.7%. In GC patients with high TC2N expression, the overall 5-year survival rate was significantly poorer than that in GC patients with low expression of TC2N (39.0% vs. 59.4%; P < 0.001, Fig. 4A). By comparing the Kaplan-Meier curves of the relapse-free survival (RFS) stratified by TC2N expression (Fig. 4B), it showed the consistent results that high level of TC2N is a signal of poor prognosis in GC patients. Furthermore, we also detected the prognostic indicator effect of TC2N expression in early (TNM stage I and II) (Fig. 4C, D) and advanced (TNM stage III and IV) (Fig. 4E,4F) gastric cancer, respectively. In early gastric cancer, the 5-year overall survival was 54.3% and 31.6% in the groups with TC2N low and high expression, respectively. And in advanced gastric cancer, the 5-year overall survival was 35.0% and 25.8% in the TC2N low and high expression groups, respectively. Similar results have been observed when RFS was used to be the comparative index. These results suggested that patients with high TC2N expression in gastric cancer tissues showed poorer prognosis than those with low TC2N expression regardless of TNM stage.
We also performed univariate Cox regression to estimate the value of prognostic evaluation of TC2N expression and the clinicopathological features for patients with gastric cancer. Univariate analysis showed that high TC2N level together with female, younger, advanced differentiation degree, large tumor size, more than two parts of stomach involved and advanced T, N, and M stage were significantly associated with poor overall survival of gastric cancer patients (Table 2). To correct the effects of confounding factors, multivariate Cox regression analysis was performed by using the method “Forward Stepwise (Conditional LR)”. It was revealed that high TC2N expression was also associated with poor survival of gastric cancer patients after adjusting for tumor size, depth of tumor invasion, lymph node metastasis and distant metastasis (HR = 1.616; 95%CI: 1.121–2.332, \( p = 0.010 \)) (Table 2). These results indicated that the protein expression of TC2N could be an independent prognostic predictor for patients with gastric cancer.
Table 2
Association of various factors with overall survival determined by Cox regression.

| Variables                  | Univariate Cox analysis |          |          | Multivariate Cox analysis |          |          |
|----------------------------|-------------------------|----------|----------|---------------------------|----------|----------|
|                            |                         | HR       | 95% CI   | P value                   | HR       | 95% CI   | P value |
| Gender                     |                         |          |          |                           |          |          |
| Male                       | 1                       |          |          |                           |          |          |
| Female                     | 1.414                   | 1.167    | 2.016    | 0.022                     |          |          |
| Age                        |                         |          |          |                           |          |          |
| < 50                       | 1                       |          |          |                           |          |          |
| ≥ 50                       | 0.624                   | 0.428    | 0.975    | 0.043                     |          |          |
| Histological classification|                         |          |          |                           |          |          |
| Well and moderately        | 1                       |          |          |                           |          |          |
|   differentiated           |                         |          |          |                           |          |          |
| Poorly differentiated      | 2.016                   | 1.679    | 3.183    | 0.001                     |          |          |
| Tumor size                 |                         |          |          |                           |          |          |
| ≤ 4 cm                     | 1                       |          |          |                           | 1        |          |
| > 4 cm                     | 2.138                   | 1.152    | 4.126    | < 0.001                   | 1.573    | 1.315    | 2.422    | 0.029 |
| Tumor location             |                         |          |          |                           |          |          |
| Upper stomach              | 1                       |          |          |                           |          |          |
| Middle stomach             | 0.945                   | 0.527    | 1.893    | 0.981                     |          |          |
| Lower stomach              | 0.695                   | 0.621    | 1.190    | 0.238                     |          |          |
| More than two parts        | 1.239                   | 1.311    | 2.678    | 0.039                     |          |          |
| Depth of invasion<sup>a</sup> |                         |          |          |                           |          |          |
| T1                         | 1                       |          |          |                           | 1        |          |
| T2                         | 1.489                   | 0.318    | 8.812    | 0.622                     | 2.012    | 0.413    | 9.879    | 0.398 |
| T3                         | 8.786                   | 2.056    | 28.745   | 0.003                     | 5.622    | 1.445    | 22.423   | 0.018 |
| T4                         | 22.773                  | 5.023    | 92.101   | < 0.001                   | 7.691    | 1.698    | 36.012   | 0.007 |
### Variables

| Variables                      | Univariate Cox analysis | Multivariate Cox analysis |
|-------------------------------|-------------------------|---------------------------|
|                               | $HR$ | 95% CI | $P$ value | $HR$ | 95% CI | $P$ value |
| Lymph node metastasis$^a$     |      |        | < 0.001   |      |        | 0.003     |
| N0                            | 1    |        |           | 1    |        |          |
| N1                            | 2.123| 1.129  | 3.147     | 0.004| 1.891  | 0.801     | 2.234 | 0.901     |
| N2                            | 6.012| 3.761  | 9.012     | < 0.001| 2.712  | 1.654     | 5.812 | 0.001     |
| N3                            | 7.071| 3.613  | 10.972    | < 0.001| 2.231  | 1.414     | 3.914 | 0.012     |
| Distant metastasis$^a$        |      |        |           |      |        |          |
| M0                            | 1    |        |           | 1    |        |          |
| M1                            | 3.418| 3.011  | 6.746     | < 0.001| 2.087  | 1.294     | 3.294 | 0.003     |
| TC2N level                    |      |        |           |      |        |          |
| Low                           | 1    |        |           | 1    |        |          |
| High                          | 2.003| 1.354  | 2.691     | < 0.001| 1.451  | 1.312     | 2.241 | 0.013     |

$^a$: The pathological diagnoses and classifications were made according to American Joint Committee on Cancer (AJCC) cancer staging manual, 7th ed.

---

**TC2N promotes gastric cancer cell proliferation, migration and invasion in vitro**

To explore the potential role of TC2N in the development of GC, TC2N was knocked-down in AGS cells or overexpressed in MKN28 cells, and the expression of TC2N was verified by WB (Fig. 5A). We then assessed the role of TC2N in cell proliferation by CCK8 assay (Fig. 5B). The data showed that TC2N knockdown markedly impeded the proliferation of AGS cells, while TC2N overexpression promoted the growth of MKN28 cells. Next, transwell assays were performed to examine the effect of TC2N on migratory and invasive capacity of GC cells. The results showed that the downregulation of TC2N inhibited the migration and invasion of AGS cells, whereas TC2N overexpression promoted the migration and invasion of MKN28 cells (Fig. 5C, D). These above results suggested that TC2N might act as a potential oncogene in gastric cancer.

---

**Analysis of genes differentially expressed in correlation with TC2N in GC**
The Function module of LinkedOmics was used to analyze mRNA sequencing data from 415 GC patients in the TCGA. As shown in the volcano plot (Fig. 6A), 3,733 genes (dark red dots) showed significant positive correlations with TC2N, whereas 5,420 genes (dark green dots) showed significant negative correlations (false discovery rate [FDR] < 0.01). The 50 significant gene sets positively and negatively correlated with TC2N as shown in the heat map (Fig. 6B, 6C). This result suggests a widespread impact of TC2N on the transcriptome. We noticed that TC2N expression showed a strong positive association with expression of CATSPERB (positive rank #1, Pearson correlation = 0.75, P = 4.694e-76) and some other genes which have been proved to be connected with cancer, such as GALNT3 (positive rank #2, Pearson correlation = 0.58, P = 5.76E-38), RBM47 (positive rank #4, Pearson correlation = 0.60, P = 1.86E-42). The scatter plot shows Pearson correlation of TC2N expression with expression of CATSPERB (Fig. 6D). In addition, we analyzed the PPI networks of TC2N by using the GeneMANIA and STRING program (Fig. 6E, 6F), and predicted a strong interaction between the proteins of TC2N and CATSPERB, as well as the proteins of TC2N and GALNT3.

**Discussion**

The present study demonstrated that high TC2N expression is significantly associated with poor prognosis and its expression may serve as a biomarker for the prognosis of patients with GC. First, we demonstrated that the TC2N expressions were significantly higher in GC by analyzing TCGA data and conducting RT-qPCR and WB to detect the expression of TC2N in tissue specimens and cells. Second, we proved that TC2N protein expression was significantly higher in GC tissues than in adjacent normal tissues, as based on tissue microarrays derived from 55 patients. Meanwhile, IHC staining of tissues from 232 GC patients verified that TC2N overexpression correlated with clinicopathological features in GC and was associated with poor OS and RFS. Third, the vitro assays proved that TC2N promoted gastric cancer cell proliferation, migration and invasion. Finally, the analysis of genes differentially expressed in correlation with TC2N in GC suggested a widespread impact of TC2N on the transcriptome and an intensive connection between TC2N and genes related to human cancer and other diseases, such as CATSPERB, GALNT3 and RBM47. Taken together, we discovered that TC2N may play a role of oncogene in gastric cancer.

Previous studies have reported the essential roles of protein containing the C2 domain in endocytosis, cellular metabolism and cancer [29–31]. TC2N expression is also associated with the prognosis and development of human lung cancer and breast cancer [16–18]. Former researchers have found that TC2N overexpression in lung cancer leads to enhancing the proliferation ability and inhibiting apoptosis through the repression of p53 function in a transcription-dependent manner. In another way, TC2N also can facilitate migration and invasion of lung cancer cells in vitro and promote tumor metastasis in vivo through increasing the degradation of IκB by promoting its phosphorylation, and subsequently activating NF-κB activity. Genes with similar expression patterns always share similar functions [32, 33]. However, TC2N was found to play a completely different role in breast cancer. TC2N is also frequently overexpressed in breast cancer, but interestingly, high TC2N expression predicts favorable prognosis in breast cancer. Further study proved that upregulation of TC2N significantly restrained breast cancer cell proliferation in vitro by blocking AKT signaling in a PI3K dependent and independent way, suggesting that
TC2N may be a tumor suppressor in breast cancer. In this study, we also demonstrated that TC2N overexpression was significantly related to the clinicopathological features in GC and promoted the its development in vitro. Bioinformatic analysis suggested a connection between TC2N and a series of genes related to human cancer and other diseases, such as CATSPERB, a novel transmembrane protein playing role in the field of reproduction [34], GALNT3, proved to play important roles in different cancers [35–37] and RBM47, reported to inhibit tumor progression in lung, breast and colon cancer [38–40]. These evidences further verified the potential role of TC2N in GC from another aspect. However, we did not explore the biological function of TC2N in vivo and the detailed mechanism are still unclear, which is a limitation of this study.

In conclusion, our results revealed that TC2N overexpression is significantly associated with poor prognosis and promotes the development of GC. TC2N may act as an independent prognostic factor in patients with GC. Further studies are required to clarify the molecular mechanisms by which TC2N promotes GC development.

**Abbreviations**

TC2N: Tac2-N; GC: Gastric cancer; TCGA: The Cancer Genome Atlas; GEPIA: Gene Expression Profiling Interactive Analysis tools; RT-qPCR: RNA isolation and reverse transcription-quantitative real-time PCR; WB: Western blot; IHC: Immunohistochemical; PPI: Protein-protein interaction; OS: Overall survival; RFS: relapse-free survival.

**Declarations**

**Ethics approval and consent to participate**

All procedures performed in studies were in accordance with the ethical standards of the Ethics Committee of the Institutional Ethical Review Board of the First Affiliated Hospital, Sun Yat-sen University.

**Consent for publication**

Not applicable

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding authors on reasonable request.

**Competing interests**

The authors declare that they have no competing interests.
Funding

This study was supported by grants from the National Natural Foundation of China (81472260, 81672343 and 81871915), Natural Science Foundation of Guangdong, China (2015A030313053 and 2017A030313570). Science and Technology Program of Guangzhou, China (201607010050). The Fundamental Research Funds for the Central Universities (15ykpy17)

Authors’ Contributions

JBX designed the research; XDO, JL, QBC, KYS, JNY and JJP performed the research; JBX and XDO analyzed the data and wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We appreciated Xingyu Zhou for polishing the manuscript.

References

1. Bray, FFerlay, J.Soerjomataram, ISiegel, RLTorre, LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Van Cutsem, ESagaert, XTopal, BHaustermans, K, Prenen H. Gastric cancer. Lancet. 2016;388(10060):2654–64.

3. Lin, YUeda, JKikuchi, STotsuka, YWei, WQQiao, YL, et al. Comparative epidemiology of gastric cancer between Japan and China. World J Gastroenterol. 2011;17(39):4421–8.

4. Sugano K. Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol. 2015;29(6):895–905.

5. Joharatnam-Hogan, NShiu, KK, Khan K. Challenges in the treatment of gastric cancer in the older patient. Cancer Treat Rev. 2020;85:101980.

6. Song, ZWu, YYang, J.Yang D, Fang X. Progress in the treatment of advanced gastric cancer. Tumour Biol. 2017;39(7):1010428317714626.

7. Mehta, RKommalapati, A, Kim RD. The Impact of Ramucirumab Treatment on Survival and Quality of Life in Patients with Gastric Cancer. Cancer Manag Res. 2020;12:51–7.

8. Wang, FHShen, L.Li, JZhou, ZWLiang, HZhang, XT, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Commun (Lond). 2019;39(1):10.

9. Digklia, AWagner, AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–14.

10. Guggenheim, DEShah, MA. Gastric cancer epidemiology and risk factors. J Surg Oncol. 2013;107(3):230–6.
11. Fukuda M, Mikoshiba K. Tac2-N, an atypical C-type tandem C2 protein localized in the nucleus. FEBS Lett. 2001;503(2–3):217–8.

12. Duncan, RR; Shipston, MJ; Chow RH. Double C2 protein. A review. Biochimie. 2000;82(5):421–6.

13. Corbalan-Garcia, S; Gomez-Fernandez, JC. Signaling through C2 domains: more than one lipid target. Biochim Biophys Acta. 2014;1838(6):1536–47.

14. Cho, W; Stahelin, RV. Membrane binding and subcellular targeting of C2 domains. Biochim Biophys Acta. 2006;1761(8):838–49.

15. Farah, C; Sossin, WS. The role of C2 domains in PKC signaling. Adv Exp Med Biol. 2012;740:663–83.

16. Hao, XL; Han, F; Zhang, N; Chen, HQ; Jiang, XY; Yin, L, et al. TC2N, a novel oncogene, accelerates tumor progression by suppressing p53 signaling pathway in lung cancer. Cell Death Differ. 2019;26(7):1235–50.

17. Hao, X; Gao, LY; Zhang, N; Chen, H; Jiang, X; Liu, W, et al. Tac2-N acts as a novel oncogene and promotes tumor metastasis via activation of NF-kappaB signaling in lung cancer. J Exp Clin Cancer Res. 2019;38(1):319.

18. Hao, XL; Gao, LY; Deng, XJ; Han, F; Chen, HQ; Jiang, X, et al. Identification of TC2N as a novel promising suppressor of PI3K-AKT signaling in breast cancer. Cell Death Dis. 2019;10(6):424.

19. Edge, SB; Compton, CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol, 2010. 17(6): p. 1471-4.

20. Xu, J; Zhang, C; He, Y; Wu, H; Wang, Z; Song, W, et al. Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer. 2012;130(4):787–97.

21. Li, J; Su, T; Yang, L; Deng, L; Zhang, C, He Y. High SLC17A9 expression correlates with poor survival in gastric carcinoma. Future Oncol, 2019.

22. Wang, Z; Wang, Z; Li, G; Wu, H; Sun, K; Chen, J, et al. CXCL1 from tumor-associated lymphatic endothelial cells drives gastric cancer cell into lymphatic system via activating integrin β1/FAK/AKT signaling. Cancer Lett. 2017;385:28–38.

23. Tomczak, KCzerwińska, P; Wiznerowicz M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Pozn). 2015;19(1a):A68–77.

24. Chandrashekar, DS; Bashel, BB; Balasubramanya, SAH; Creighton, CJP; Ponce-Rodriguez, I; Chakravarthi, B, et al. UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses. Neoplasia. 2017;19(8):649–58.

25. Tang, Z; Li, CK; Kang, B; Gao, GL; Li, C; Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98-w102.

26. Vasaikar, SV; Straub, PW; Wang, J; Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956-d963.

27. Warde-Farley, DD; Donaldson, SL; Comes, O; Zuberi, KB; Badrawi, R; Chao, P, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res, 2010. 38(Web Server issue): p. W214-20.
28. Szklarczyk, DGable, AL.Lyon D.Junge, AWyder, SHuerta-Cepas, J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607-d613.

29. Kumar, SOien, DBKhurana, ACliby, W.Hartmann L.Chien J, et al. Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer. Front Onco. 2019;9:986.

30. Han Q.Lin, XZhang, X.Jiang, GZhang, YMiao, Y, et al. WWC3 regulates the Wnt and Hippo pathways via Dishevelled proteins and large tumour suppressor 1, to suppress lung cancer invasion and metastasis. J Pathol. 2017;242(4):435–47.

31. Scott, JL.Frick, CTJohnson, KALiu, H.Yong, SSVarney, AG, et al. Molecular Analysis of Membrane Targeting by the C2 Domain of the E3 Ubiquitin Ligase Smurf1. Biomolecules, 2020. 10(2).

32. Lee, HKHsu, AKSajdak, JQin, J, Pavlidis P. Coexpression analysis of human genes across many microarray data sets. Genome Res. 2004;14(6):1085–94.

33. Jiang Q.Ma, RWang, J.Wu, XJin, SPeng, J, et al. LncRNA2Function: a comprehensive resource for functional investigation of human IncRNAs based on RNA-seq data. BMC Genom. 2015;16 Suppl 3:S2.

34. Liu J.Xia, JCho, KHClapham, DE, Ren D. CatSperbeta, a novel transmembrane protein in the CatSper channel complex. J Biol Chem. 2007;282(26):18945–52.

35. Liu, BPan, SXiao, Y.Liu, QXu, J, Jia L. LINC01296/miR-26a/GALNT3 axis contributes to colorectal cancer progression by regulating O-glycosylated MUC1 via PI3K/AKT pathway. J Exp Clin Cancer Res. 2018;37(1):316.

36. Mochizuki, YIto, KIzumi, HKohno, K, Amano J. Expression of polypeptide N-acetylgalactosaminyl transferase-3 and its association with clinicopathological factors in thyroid carcinomas. Thyroid. 2013;23(12):1553–60.

37. Miyahara, NShoda, J.Kawamoto, TFurukawa, M.Ueda, TTodoroki, T, et al. Expression of UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase isozyme 3 in the subserosal layer correlates with postsurgical survival of pathological tumor stage 2 carcinoma of the gallbladder. Clin Cancer Res. 2004;10(6):2090–9.

38. Sakurai, TIsogaya, KSakai, SMorikawa, MMorishita, YEhata, S, et al. RNA-binding motif protein 47 inhibits Nrf2 activity to suppress tumor growth in lung adenocarcinoma. Oncogene. 2017;36(35):5083.

39. Rokavec, MKaller, MHorst, D, Hermeking H. Pan-cancer EMT-signature identifies RBM47 downregulation during colorectal cancer progression. Sci Rep. 2017;7(1):4687.

40. Vanharanta, SMarney, CBShu, WValiente, M.Zou, YMele, A, et al. Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. Elife, 2014. 3.

Figures
Figure 1

TC2N transcription in subgroups of patients with gastric cancer (UALCAN). (A) Boxplot showing relative expression of TC2N in normal and GC samples. (B) Boxplot showing relative expression of TC2N in normal individuals of either gender or male or female GC patients. (C) Boxplot showing relative expression of TC2N in normal individuals of any age or in GC patients aged 21–40, 41–60, 61–80, or 81–100 yrs. (D) Boxplot showing relative expression of TC2N in normal individuals of any ethnicity or in GC patients of Caucasian, African-American or Asian ethnicity. (E) Boxplot showing relative expression of TC2N in normal individuals or in GC patients in stages 1, 2, 3 or 4. (F) Boxplot showing relative expression of TC2N in normal individuals or GC patients with grade 1, 2 or 3 tumors. (G) Boxplot showing relative expression of TC2N in normal individuals or GC patients with or without TP53 mutation. (H) Boxplot showing relative expression of TC2N in normal individuals or GC patients with or without H.pylori infection. Data are mean ± SE. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Figure 2

High TC2N expression in gastric cancer. (A) Analysis of TC2N expression in unpaired GC (T = 408) and normal tissues (N = 211) in the GEPIA (P<0.05). (B, C) The measurements of TC2N expression in gastric cancer cell lines compared with the normal cell line GES1 by qRT-PCR(B) and WB(C). (D, E) The measurements of TC2N expression in 12 paired GC tissues and matched normal adjacent mucosa, analyzed by qRT-PCR(D) and WB(E). T, GC tissues; N, matched normal adjacent mucosa. *, P < 0.05.
Figure 3

TC2N protein expression in GC tissues and adjacent normal tissues. (A) IHC staining of the TC2N protein in GC tissues. (B) IHC staining of the TC2N protein in adjacent normal tissues. (C) TC2N protein expression was higher in GC specimens than in adjacent normal tissues, as indicated by IHC staining. (D) Percentage of patients with GC according to TC2N protein expression as indicated by IHC scoring.
Figure 4

High TC2N expression indicated worse prognosis in patients with gastric cancer. (A-B) Patients with high expression of TC2N had a worse overall survival (A) and relapse-free survival (B) than those with low TC2N expression (P< 0.01). (C-D) High TC2N expression in gastric cancer tissues indicated worse overall survival (C) and relapse-free survival (D) in patients with early stage gastric cancer (TNM stage: I and II). (E-F) High TC2N expression in gastric cancer tissues predicted worse overall survival (E) and relapse-free survival (F) in patients with advanced gastric cancer (TNM stage: III and IV).
Figure 5

Effects of ectopic expression of TC2N on gastric cancer cell proliferation migration and invasion in vitro. (A) Knockdown of TC2N in AGS cells and overexpression of TC2N in MKN28 cells were identified by WB assay. β-actin serves as a loading control. (B) CCK8 assays were carried out in AGS cells expressing the negative control or siRNA of TC2N and in MKN28 cells expressing the vector control or TC2N. (C, D) Migration and invasion assays were carried out in AGS cells expressing the negative control or siRNA of TC2N and in MKN28 cells expressing the vector control or TC2N. **, P< 0.01. ***, P< 0.001.
Figure 6

Genes differentially expressed in correlation with TC2N in gastric carcinoma (LinkedOmics). (A) A Spearman test was used to analyze correlations between TC2N and genes differentially expressed in GC. (B, C) Heat maps showing genes positively and negatively correlated with TC2N in GC (TOP 50). Red indicates positively correlated genes and green indicates negatively correlated genes. (D) The scatter plot shows Pearson correlation of TC2N expression with expression of CATSPERB. (E) Protein-protein interaction network of TC2N-target networks (GeneMANIA). (F) The interaction network of the TC2N-correlated genes in GC (STRING).